Use of docetaxel (Taxotere®) in patients with paclitaxel (Taxol®) hypersensitivity

Chulso Moon, Claire F. Verschraegen, Michael Bevers, Ralph Freedman, Andrzej P. Kudelka, John J. Kavanagh

Research output: Contribution to journalArticle

Abstract

Anaphylaxis or significant hypersensitivity reaction is one of the most catastrophic potential complications of chemotherapy. There is a 2-5% risk of hypersensitivity with paclitaxel, a commonly used chemotherapeutic agent for various cancers. Three patients, who developed hypersensitivity to paclitaxel infusion, received docetaxel without allergic reactions. Docetaxel may therefore be an alternative treatment for patients with paclitaxel hypersensitivity. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish (US)
Pages (from-to)565-568
Number of pages4
JournalAnti-Cancer Drugs
Volume11
Issue number7
DOIs
StatePublished - 2000
Externally publishedYes

Keywords

  • Allergic reactions
  • Ovarian neoplasms
  • Taxane

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Use of docetaxel (Taxotere®) in patients with paclitaxel (Taxol®) hypersensitivity'. Together they form a unique fingerprint.

  • Cite this

    Moon, C., Verschraegen, C. F., Bevers, M., Freedman, R., Kudelka, A. P., & Kavanagh, J. J. (2000). Use of docetaxel (Taxotere®) in patients with paclitaxel (Taxol®) hypersensitivity. Anti-Cancer Drugs, 11(7), 565-568. https://doi.org/10.1097/00001813-200008000-00007